カテゴリ： MarketsandMarkets, 世界, 医療/バイオ

ニューロモデュレーションのグローバル市場予測（～2028）：内部（脊髄刺激、脳深部刺激）、外部（経頭蓋磁気刺激）

■ 英語タイトル：Neuromodulation Market by Type (Internal (Spinal Cord Stimulation, Deep Brain Stimulation), External (Transcranial Magnetic Stimulation), Application (Tremor, Epilepsy, Parkinson's Disease, Depression, Gastroparesis), and Region - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート（データ管理コード：BT3571-24）■ 発行会社/調査会社：MarketsandMarkets
■ 商品コード：BT3571-24
■ 発行日：2024年2月2日
■ 調査対象地域：グローバル
■ 産業分野：バイオテクノロジー
■ ページ数：204
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ニューロモデュレーションのグローバル市場予測（～2028）：内部（脊髄刺激、脳深部刺激）、外部（経頭蓋磁気刺激）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

"世界のニューロモデュレーション市場は、2023年に推定62億米ドルと評価され、予測期間中に12.0％のCAGRで、2028年までに110億米ドルに達すると予測"市場成長の原動力は、神経疾患や神経損傷の流行、先進的なニューロモデュレーションおよび神経刺激技術の開発への注目の高まり、老人人口の増加とそれに伴う神経疾患の有病率の増加、神経疾患の研究に対する政府の支援、ニューロモデュレーションデバイスの償還の利用可能性、ニューロモデュレーションデバイスを開発するためのデバイスメーカー、医療提供者、研究機関の協力などの要因です。

"タイプ別では、体内ニューロモデュレーションがニューロモデュレーション市場を支配"
タイプ別では、世界のニューロモデュレーション市場は内部ニューロモデュレーションと外部ニューロモデュレーションに分類されます。2022年には、内部ニューロモデュレーションがニューロモデュレーション市場で最大の貢献です。市場成長の主な要因は、コスト削減、低侵襲性、身体的影響の軽減、生活の質の向上などに関連する長期的なものです。

"予測期間中、脳深部刺激療法セグメントは内部ニューロモデュレーションタイプの中でかなりの速度で成長"
ニューロモデュレーション市場は、タイプ別に深部脳刺激、脊髄刺激、迷走神経刺激、仙骨神経刺激、胃電気刺激に区分されます。パーキンソン病やうつ病などの対象疾患の増加や、各社がこの分野での製品の発売や承認に注力していることです。これらの推進要因が市場成長を後押ししています。

"アジア太平洋：ニューロモデュレーション市場において最も急成長している地域"
世界のニューロモデュレーション市場は、北米、欧州、アジア太平洋地域、その他の地域の5地域に区分されます。アジア太平洋地域は、ニューロモデュレーション市場において予測期間中に最も高い成長率が見込まれています。同地域の高成長は、主に老年人口の増加、高齢者層における神経疾患の高い疾病負担に起因しています。

ニューロモデュレーション市場の主要参入企業のプロファイルの内訳です。

-企業タイプ別：Tier 1 28%、Tier 2 42%、Tier 3 30%
-役職別：Cレベル：30％、Dレベル：34％、その他：36%
-地域別：北米46％、欧州25％、アジア太平洋地域18％、その他11%

この市場の主なプレーヤーは、Medtronic (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), LivaNova (UK), NeuroPace (US), Neuronetics (US), Helius Medical Technologies (US), Renishaw (UK), Bioinduction (UK), Axonics (US), Nevro Corporation (US), BlueWind Medical (Israel), Aleva Neurotherapeutics (Switzerland), GiMer Medical (Taiwan), NeuroSigma (US), BioWaveGo USA (US), Synapse Biomedical (US), Theranica Bio-Electronics (Israel), MicroTransponder (US), Soterix Medical (US), Saluda Medical (US), Electrocore, Inc. (US), Magstim (UK), BIOTRONIK (Germany), tVNS Technologies (Germany)です。

調査範囲
この調査レポートは、ニューロモデュレーション市場をタイプ別（内部、外部）、内部（脊髄刺激（SCS）、脳深部刺激（DBS）、迷走神経刺激（VNS）、仙骨神経刺激（SNS）、胃電気刺激（GES））、用途（脊髄刺激（故障性腰症候群、慢性疼痛、虚血）、脳深部刺激（パーキンソン病、振戦、うつ病、 その他のDBS応用）、仙骨神経刺激（尿失禁、便失禁）、迷走神経刺激（てんかん、その他のてんかん応用）、胃電気刺激（胃下垂、肥満）、経皮電気神経刺激（治療抵抗性うつ病、その他のTENS応用）、経頭蓋磁気刺激（偏頭痛、うつ病）、地域（北米、欧州、アジア太平洋地域、その他の地域）に分類しています。ニューロモデュレーション市場の成長に影響を与える促進要因、機会、課題などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、提供製品、主要戦略、買収、パートナーシップに関する洞察を提供します。ニューロモデュレーション市場に関連する新製品の発売や承認、最近の動向。ニューロモデュレーション市場のエコシステムにおける今後の新興企業の競争分析もカバーしています。

このレポートを購入する理由
本レポートは、ニューロモデュレーション市場全体およびサブセグメントの収益数の最も近い近似値に関する情報を提供することで、同市場の市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、当レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します。
-ニューロモデュレーション市場の成長に影響を与える主な促進要因（神経疾患の有病率の上昇、ニューロモデュレーションの応用範囲の拡大、神経変性疾患に対する意識の高まり）、機会（ニューロモデュレーションの応用範囲の拡大、新興国における人口の多さと医療費の増加）、課題（厳しい規制の枠組みと時間のかかる承認プロセス、訓練を受けた専門家の不足、製品回収）の分析を提供します。
-製品開発/イノベーション：ニューロモデュレーション市場の今後の技術、研究開発活動、新製品発売に関する詳細な洞察を提供します。
-市場開発：有利な市場に関する包括的な情報 - 当レポートでは、さまざまな地域のニューロモデュレーション市場を分析しています。
-市場の多様化：新製品、未開拓の地域、最近の動向、ニューロモデュレーション市場における投資などに関する詳細な情報を提供します。
-競合評価：ニューロモデュレーション市場戦略におけるMedtronic (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), LivaNova (UK), NeuroPace (US)などの主要企業の市場シェア、成長戦略、製品提供などを詳細に評価しています。

1 イントロダクション
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 ニューロモデュレーションの世界市場規模：種類別
7 ニューロモデュレーションの世界市場規模：用途別
8 ニューロモデュレーションの世界市場規模：地域別
9 競争状況
10 企業情報
11 付録

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 31
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.3.2 YEARS CONSIDERED 33
1.3.3 CURRENCY CONSIDERED 33
1.4 STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Secondary sources 37
2.1.2 PRIMARY DATA 37
2.1.2.1 Key data from primary sources 38
2.1.2.2 Key industry insights 39
2.1.2.3 Breakdown of primary interviews: supply- and demand-side participants 39
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE) 40
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE) 40
2.2 MARKET SIZE ESTIMATION 41
2.2.1 BOTTOM-UP APPROACH 41
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 41
FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 42
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 43
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION 44
2.4 MARKET SHARE ASSESSMENT 45
2.5 ASSUMPTIONS 45
2.6 RISK ASSESSMENT 45
2.7 RESEARCH LIMITATIONS 46
2.7.1 METHODOLOGY-RELATED LIMITATIONS 46
2.7.2 SCOPE-RELATED LIMITATIONS 46
2.8 IMPACT OF RECESSION ON NEUROMODULATION MARKET 46
3 EXECUTIVE SUMMARY 47
FIGURE 8 NEUROMODULATION MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 9 NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 10 NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 11 NEUROMODULATION MARKET, BY REGION 49
4 PREMIUM INSIGHTS 50
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN NEUROMODULATION MARKET 50
FIGURE 12 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO CREATE LUCRATIVE OPPORTUNITIES FOR MARKET PLAYERS 50
4.2 NORTH AMERICAN NEUROMODULATION MARKET, BY TYPE AND COUNTRY 51
FIGURE 13 INTERNAL NEUROMODULATION SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF NORTH AMERICAN MARKET IN 2022 51
4.3 NEUROMODULATION MARKET, BY COUNTRY 52
FIGURE 14 CHINA TO REGISTER HIGHEST CAGR IN NEUROMODULATION MARKET DURING FORECAST PERIOD 52
4.4 NEUROMODULATION MARKET, BY REGION 53
FIGURE 15 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 53
4.5 NEUROMODULATION MARKET: DEVELOPED VS. DEVELOPING MARKETS 53
FIGURE 16 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 17 NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES, AND TRENDS 54
5.2.1 DRIVERS 55
5.2.1.1 Rising prevalence of neurological disorders and nerve injuries 55
5.2.1.2 Increasing focus on development of advanced neuromodulation and neurostimulation technologies 55
5.2.1.3 Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices 56
5.2.1.4 Growing geriatric population and subsequent increase in prevalence of neurological disorders 56
5.2.1.5 Availability of reimbursements for neuromodulation devices 56
5.2.1.6 Government-led support for research on neurological disorders 57
5.2.2 RESTRAINTS 57
5.2.2.1 High cost of neuromodulation procedures 57
5.2.2.2 Preference for drug therapies over neuromodulation products 57
5.2.2.3 Adverse effects and complications associated with neuromodulation devices 58
TABLE 1 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT NEUROMODULATION DEVICES 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Large population and increasing healthcare expenditure in emerging economies 58
5.2.3.2 Widening application scope of neuromodulation 58
TABLE 2 INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS 59
FIGURE 18 PUBLISHED RESEARCH PAPERS, 2013–2022 59
5.2.4 CHALLENGES 60
5.2.4.1 Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices 60
5.2.4.2 Shortage of trained professionals 60
5.2.4.3 Product recalls 60
TABLE 3 MAJOR PRODUCT RECALLS 60
5.2.5 TRENDS 61
5.2.5.1 Role of artificial intelligence (AI) in advancing neuromodulation 61
5.3 VALUE CHAIN ANALYSIS 61
FIGURE 19 NEUROMODULATION MARKET: VALUE CHAIN ANALYSIS 61
5.3.1 RESEARCH AND DEVELOPMENT (R&D) 62
5.3.2 MANUFACTURING AND ASSEMBLY 62
5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 62
5.4 SUPPLY CHAIN ANALYSIS 62
FIGURE 20 DIRECT DISTRIBUTION—PREFERRED STRATEGY OF PROMINENT COMPANIES 63
5.5 TECHNOLOGY ANALYSIS 63
5.6 PORTER’S FIVE FORCES ANALYSIS 64
TABLE 4 NEUROMODULATION MARKET: PORTER’S FIVE FORCES ANALYSIS 64
5.6.1 THREAT OF NEW ENTRANTS 64
5.6.2 INTENSITY OF COMPETITIVE RIVALRY 64
5.6.3 BARGAINING POWER OF BUYERS 64
5.6.4 BARGAINING POWER OF SUPPLIERS 64
5.6.5 THREAT OF SUBSTITUTES 65
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA 65
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 65
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 65
TABLE 5 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS BY END USER 65
5.7.2 BUYING CRITERIA 65
FIGURE 22 KEY BUYING CRITERIA BY END USER 65
5.8 REGULATORY LANDSCAPE 66
TABLE 6 LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION 66
5.8.1 REGULATORY LANDSCAPE, BY REGION 67
5.8.1.1 North America 67
5.8.1.1.1 US 67
TABLE 7 CLASSIFICATION OF MEDICAL DEVICES BY US FDA 67
5.8.1.2 Europe 67
5.8.1.3 Asia Pacific 68
5.8.1.3.1 India 68
5.8.1.3.2 China 68
TABLE 8 NMPA MEDICAL DEVICES CLASSIFICATION 68
5.8.1.4 Japan 68
TABLE 9 JAPAN: CLASSIFICATION OF MEDICAL DEVICES 68
5.9 PATENT ANALYSIS 69
5.10 KEY CONFERENCES AND EVENTS, 2024–2025 69
TABLE 10 NEUROMODULATION MARKET: LIST OF CONFERENCES AND EVENTS, 2024–2025 69
5.11 PRICING ANALYSIS 71
TABLE 11 PRICE RANGE OF NEUROMODULATION DEVICES AND PROCEDURES, 2022 71
5.12 TRADE ANALYSIS 72
TABLE 12 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2018–2022 (USD MILLION) 72
TABLE 13 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2018–2022 (USD MILLION) 72
5.13 ECOSYSTEM MAPPING 73
FIGURE 23 NEUROMODULATION MARKET: ECOSYSTEM MAPPING 73
TABLE 14 COMPANIES AND THEIR ROLES IN NEUROMODULATION ECOSYSTEM 73
FIGURE 24 KEY PLAYERS IN NEUROMODULATION MARKET 74
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
6 NEUROMODULATION MARKET, BY TYPE 75
6.1 INTRODUCTION 76
TABLE 15 NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 76
6.2 INTERNAL NEUROMODULATION 76
TABLE 16 INTERNAL: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 77
TABLE 17 INTERNAL: NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION) 77
6.2.1 SPINAL CORD STIMULATION 77
6.2.1.1 Growing incidence of spinal cord injuries to fuel market growth 77
TABLE 18 SPINAL CORD STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 79
TABLE 19 INTERNAL: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY REGION, 2021–2028 (USD MILLION) 79
6.2.2 DEEP BRAIN STIMULATION 80
6.2.2.1 Growing use to control debilitating symptoms caused by neurological disorders to drive market 80
TABLE 20 DEEP BRAIN STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 81
TABLE 21 INTERNAL: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2021–2028 (USD MILLION) 81
6.2.3 VAGUS NERVE STIMULATION 81
6.2.3.1 Rising geriatric population and high incidence of epilepsy to drive market 81
TABLE 22 VAGUS NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 82
TABLE 23 INTERNAL: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION) 82
6.2.4 SACRAL NERVE STIMULATION 82
6.2.4.1 Widening application scope of sacral nerve stimulation to drive market 82
TABLE 24 SACRAL NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 83
TABLE 25 INTERNAL: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION) 83
6.2.5 GASTRIC ELECTRICAL STIMULATION 84
6.2.5.1 Growing number of people suffering from severe gastroesophageal reflux disease (GERD) and gastroparesis to fuel market growth 84
TABLE 26 GASTRIC ELECTRICAL STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 84
TABLE 27 INTERNAL: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY REGION, 2021–2028 (USD MILLION) 84
6.3 EXTERNAL NEUROMODULATION 85
TABLE 28 EXTERNAL NEUROMODULATION: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 85
TABLE 29 EXTERNAL NEUROMODULATION: NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION) 85
6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 86
6.3.1.1 Extensive use in healthcare sector, low cost, and ease of use to fuel market growth 86
TABLE 30 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES 86
TABLE 31 EXTERNAL: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION) 87
6.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) 87
6.3.2.1 Minimal patient discomfort associated with transcranial magnetic stimulation (TMS) to support demand 87
TABLE 32 TRANSCRANIAL MAGNETIC STIMULATION DEVICE OFFERED BY MAJOR COMPANIES 87
TABLE 33 EXTERNAL: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2021–2028 (USD MILLION) 88
6.3.3 RESPIRATORY ELECTRICAL STIMULATION 88
6.3.3.1 High treatment efficacy to fuel market growth 88
TABLE 34 RESPIRATORY ELECTRICAL STIMULATION DEVICE OFFERED BY MAJOR COMPANIES 88
TABLE 35 EXTERNAL: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2021–2028 (USD MILLION) 89
 
7 NEUROMODULATION MARKET, BY APPLICATION 90
7.1 INTRODUCTION 91
7.2 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION 91
TABLE 36 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 91
7.2.1 CHRONIC PAIN 91
7.2.1.1 High incidence of chronic pain to support market growth 91
TABLE 37 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2021–2028 (USD MILLION) 92
7.2.2 FAILED BACK SURGERY SYNDROME (FBSS) 92
7.2.2.1 Increasing incidence of failed back surgery syndrome (FBSS) with rising number of surgeries annually to drive demand 92
TABLE 38 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2021–2028 (USD MILLION) 93
7.2.3 ISCHEMIA 93
7.2.3.1 High effectiveness of neuromodulation for ischemia treatment to support market growth 93
TABLE 39 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2021–2028 (USD MILLION) 93
7.3 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION 94
TABLE 40 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 94
7.3.1 PARKINSON’S DISEASE 94
7.3.1.1 Rising incidence of Parkinson’s disease and growing R&D for innovation to drive market 94
TABLE 41 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2021–2028 (USD MILLION) 95
7.3.2 TREMORS 95
7.3.2.1 High efficacy of deep brain stimulation (DBS) in treating tremors to boost demand 95
TABLE 42 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2021–2028 (USD MILLION) 95
7.3.3 DEPRESSION 96
7.3.3.1 Rising research and clinical studies related to depression treatment to drive market 96
TABLE 43 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION) 96
7.3.4 OTHER DBS APPLICATIONS 96
TABLE 44 DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 97
7.4 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION 97
TABLE 45 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 97
7.4.1 URINE INCONTINENCE 98
7.4.1.1 High incidence of urine incontinence to create growth opportunities 98
TABLE 46 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2021–2028 (USD MILLION) 98
7.4.2 FECAL INCONTINENCE 98
7.4.2.1 Reduced symptom recurrence with use of SNS in fecal incontinence treatment to drive demand 98
TABLE 47 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2021–2028 (USD MILLION) 99
7.5 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION (VNS), BY APPLICATION 99
TABLE 48 NEUROMODULATION MARKET FOR VAGUS NERVE SIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 99
7.5.1 EPILEPSY 99
7.5.1.1 Advantages associated with VNS in epilepsy treatment to propel market growth 99
TABLE 49 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2021–2028 (USD MILLION) 100
7.5.2 OTHER VNS APPLICATIONS 100
TABLE 50 VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 100
7.6 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION 101
TABLE 51 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 101
7.6.1 GASTROPARESIS 101
7.6.1.1 Reduced hospitalization time for patients affected by gastroparesis by GES treatment to drive market 101
TABLE 52 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2021–2028 (USD MILLION) 101
7.6.2 OBESITY 102
7.6.2.1 High prevalence of obesity and risks associated with gastric bypass to fuel demand 102
TABLE 53 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2021–2028 (USD MILLION) 102
7.7 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION 102
TABLE 54 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 102
7.7.1 TREATMENT-RESISTANT DEPRESSION 103
7.7.1.1 Increasing prevalence of depression to boost market growth 103
TABLE 55 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2021–2028 (USD MILLION) 103
7.7.2 OTHER TENS APPLICATIONS 103
TABLE 56 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 104
 
7.8 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION 104
TABLE 57 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 104
TABLE 58 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION) 104
7.8.1 DEPRESSION 105
7.8.1.1 High effectiveness of TMS and increased acceptance among patients to drive market 105
TABLE 59 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION) 105
7.8.2 MIGRAINE 105
7.8.2.1 High prevalence of migraine to support market growth 105
TABLE 60 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2021–2028 (USD MILLION) 106
7.9 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION 106
7.9.1 SPINAL CORD INJURY 106
7.9.1.1 Rising incidence of spinal cord injuries to fuel demand 106
TABLE 61 RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2021–2028 (USD MILLION) 106
8 NEUROMODULATION MARKET, BY REGION 107
8.1 INTRODUCTION 108
TABLE 62 NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION) 108
8.2 NORTH AMERICA 108
FIGURE 26 NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT 109
TABLE 63 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 64 NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 65 NORTH AMERICA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 66 NORTH AMERICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 67 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 68 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 69 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 70 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 71 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 72 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 73 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 113
8.2.1 US 113
8.2.1.1 Large presence of prominent players to drive market 113
FIGURE 27 PROJECTED NUMBER OF PEOPLE WITH ALZHEIMER’S DEMENTIA IN US, 2020–2060 (MILLION) 114
TABLE 74 US FDA-APPROVED PRODUCTS, 2019–2022 114
TABLE 75 US: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 76 US: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 77 US: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 115
8.2.2 CANADA 116
8.2.2.1 Rising healthcare expenditure and increasing prevalence of chronic diseases to drive demand 116
TABLE 78 NEUROLOGICAL CONDITIONS PREVALENT IN CANADA, 2016–2031 116
TABLE 79 CANADA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 80 CANADA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 81 CANADA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 118
8.2.3 NORTH AMERICAN NEUROMODULATION MARKET: RECESSION IMPACT 118
8.3 EUROPE 118
TABLE 82 PREVALENCE OF DEMENTIA, BY COUNTRY, 2018 & 2050 119
TABLE 83 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 84 EUROPE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 85 EUROPE: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 86 EUROPE: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 87 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 88 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 89 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 90 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 91 EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 92 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 123
TABLE 93 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 123
8.3.1 GERMANY 123
8.3.1.1 Increasing healthcare expenditure and presence of favorable reimbursement policies to drive market 123
TABLE 94 GERMANY: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 95 GERMANY: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 96 GERMANY: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 125
8.3.2 UK 125
8.3.2.1 Rising healthcare expenditure and high public- and private-sector investments to fuel market growth 125
TABLE 97 UK: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 98 UK: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 99 UK: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 126
8.3.3 FRANCE 126
8.3.3.1 Availability of insurance and favorable healthcare reforms to drive market 126
TABLE 100 FRANCE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 101 FRANCE: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 102 FRANCE: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 128
8.3.4 ITALY 128
8.3.4.1 Easy access to healthcare services to create lucrative opportunities for market 128
TABLE 103 ITALY: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 104 ITALY: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 105 ITALY: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 129
8.3.5 SPAIN 130
8.3.5.1 Growing government-led initiatives related to healthcare to support market growth 130
TABLE 106 SPAIN: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 107 SPAIN: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 108 SPAIN: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 131
8.3.6 REST OF EUROPE 131
TABLE 109 REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 110 REST OF EUROPE: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 111 REST OF EUROPE: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 132
8.3.7 EUROPEAN NEUROMODULATION MARKET: RECESSION IMPACT 132
8.4 ASIA PACIFIC 133
FIGURE 28 ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT 133
TABLE 112 ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 113 ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 114 ASIA PACIFIC: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 115 ASIA PACIFIC: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 116 ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 135
TABLE 117 ASIA PACIFIC: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 135
TABLE 118 SIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 119 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 120 ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 121 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 122 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 137
8.4.1 JAPAN 137
8.4.1.1 Increasing prevalence of neurological disorders to drive demand 137
TABLE 123 JAPAN: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 124 JAPAN: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 125 JAPAN: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 139
8.4.2 CHINA 139
8.4.2.1 Growing geriatric population to fuel demand 139
TABLE 126 CHINA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 127 CHINA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 128 CHINA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 140
8.4.3 INDIA 140
8.4.3.1 Improvements in healthcare infrastructure to contribute to market growth 140
TABLE 129 INDIA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 130 INDIA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 131 INDIA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 141
8.4.4 REST OF ASIA PACIFIC 142
TABLE 132 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 133 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 134 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 143
8.4.5 ASIA PACIFIC NEUROMODULATION MARKET: RECESSION IMPACT 143
8.5 ROW 144
TABLE 135 ROW: NEUROMODULATION MARKET, BY COUNTRY/REGION, 2021–2028 (USD MILLION) 144
TABLE 136 ROW: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 137 ROW: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 138 ROW: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 139 ROW: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 145
TABLE 140 ROW: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 141 ROW: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 142 ROW: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 143 ROW: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 144 ROW: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 145 ROW: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION) 147
8.5.1 LATIN AMERICA 148
8.5.1.1 Increasing cases of depressive and post-traumatic stress disorders to drive demand 148
TABLE 146 LATIN AMERICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 147 LATIN AMERICA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 148 LATIN AMERICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 149
8.5.2 MIDDLE EAST & AFRICA 149
8.5.2.1 Improvements in healthcare infrastructure and growing awareness regarding neuromodulation to drive market 149
TABLE 149 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 150 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 151 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE, 2021–2028 (USD MILLION) 151
8.5.3 GCC COUNTRIES 151
TABLE 152 GCC COUNTRIES: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 153 GCC COUNTRIES: NEUROMODULATION MARKET FOR INTERNAL, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 154 GCC COUNTRIES: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
8.5.4 ROW NEUROMODULATION MARKET: RECESSION IMPACT 152
9 COMPETITIVE LANDSCAPE 153
9.1 OVERVIEW 153
9.2 STRATEGIES ADOPTED BY KEY PLAYERS 153
TABLE 155 NEUROMODULATION MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 153
9.3 REVENUE SHARE ANALYSIS, 2020–2022 154
FIGURE 29 NEUROMODULATION MARKET: REVENUE ANALYSIS OF FIVE KEY PLAYERS, 2020–2022 154
9.4 MARKET SHARE ANALYSIS, 2022 155
TABLE 156 NEUROMODULATION MARKET: DEGREE OF COMPETITION 155
9.5 COMPANY EVALUATION MATRIX, 2022 156
9.5.1 STARS 156
9.5.2 EMERGING LEADERS 156
9.5.3 PERVASIVE PLAYERS 156
9.5.4 PARTICIPANTS 156
FIGURE 30 NEUROMODULATION MARKET: COMPANY EVALUATION MATRIX, 2022 157
9.5.5 COMPANY FOOTPRINT 157
TABLE 157 OVERALL COMPANY FOOTPRINT 157
TABLE 158 COMPANY REGION FOOTPRINT 158
TABLE 159 COMPANY TYPE FOOTPRINT 159
9.6 START-UPS/SMALL AND MEDIUM-SIZED ENTERPRISES (SMES) EVALUATION MATRIX, 2022 160
9.6.1 PROGRESSIVE COMPANIES 160
9.6.2 STARTING BLOCKS 160
9.6.3 RESPONSIVE COMPANIES 160
9.6.4 DYNAMIC COMPANIES 161
FIGURE 31 NEUROMODULATION MARKET: START-UPS/SMES EVALUATION MATRIX, 2022 161
9.6.5 COMPETITIVE BENCHMARKING 162
TABLE 160 NEUROMODULATION MARKET: LIST OF KEY START-UPS/SMES 162
 
9.7 COMPETITIVE SCENARIOS AND TRENDS 162
9.7.1 PRODUCT LAUNCHES & APPROVALS 162
TABLE 161 NEUROMODULATION MARKET: PRODUCT LAUNCHES & APPROVALS, 2020–2023 162
9.7.2 DEALS 163
TABLE 162 NEUROMODULATION MARKET: DEALS, 2020–2023 163
10 COMPANY PROFILES 164
(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*
10.1 KEY PLAYERS 164
10.1.1 MEDTRONIC PLC 164
TABLE 163 MEDTRONIC PLC: COMPANY OVERVIEW 164
FIGURE 32 MEDTRONIC PLC: COMPANY SNAPSHOT 165
TABLE 164 MEDTRONIC PLC: PRODUCT APPROVALS 167
TABLE 165 MEDTRONIC PLC: DEALS 167
10.1.2 BOSTON SCIENTIFIC CORPORATION 169
TABLE 166 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 169
FIGURE 33 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 170
TABLE 167 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES AND APPROVALS 171
TABLE 168 BOSTON SCIENTIFIC CORPORATION: DEALS 172
10.1.3 ABBOTT LABORATORIES 173
TABLE 169 ABBOTT LABORATORIES: COMPANY OVERVIEW 173
FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT 174
TABLE 170 ABBOTT LABORATORIES: PRODUCT LAUNCHES AND APPROVALS 175
10.1.4 LIVANOVA PLC 176
TABLE 171 LIVANOVA PLC: COMPANY OVERVIEW 176
FIGURE 35 LIVANOVA PLC: COMPANY SNAPSHOT 177
TABLE 172 LIVANOVA PLC: PRODUCT APPROVALS 178
TABLE 173 LIVANOVA PLC: DEALS 178
10.1.5 NEVRO CORPORATION 179
TABLE 174 NEVRO CORPORATION: COMPANY OVERVIEW 179
FIGURE 36 NEVRO CORPORATION: COMPANY SNAPSHOT 179
TABLE 175 NEVRO CORPORATION: PRODUCT APPROVALS 180
TABLE 176 NEVRO CORPORATION: DEALS 180
10.1.6 NEUROSIGMA, INC. 181
TABLE 177 NEUROSIGMA, INC.: COMPANY OVERVIEW 181
TABLE 178 NEUROSIGMA, INC.: PRODUCT LAUNCHES & APPROVALS 182
TABLE 179 NEUROSIGMA, INC.: DEALS 182
TABLE 180 NEUROSIGMA, INC.: OTHERS 183
10.1.7 NEUROPACE, INC. 184
 
TABLE 181 NEUROPACE, INC.: COMPANY OVERVIEW 184
FIGURE 37 NEUROPACE, INC.: COMPANY SNAPSHOT 184
TABLE 182 NEUROPACE, INC.: PRODUCT LAUNCHES & APPROVALS 185
TABLE 183 NEUROPACE, INC.: OTHERS 185
10.1.8 SOTERIX MEDICAL INC. 186
TABLE 184 SOTERIX MEDICAL INC.: COMPANY OVERVIEW 186
TABLE 185 NEUROPACE, INC.: OTHERS 187
10.1.9 SYNAPSE BIOMEDICAL INC. 188
TABLE 186 SYNAPSE BIOMEDICAL INC.: COMPANY OVERVIEW 188
10.1.10 ALEVA NEUROTHERAPEUTICS SA 189
TABLE 187 ALEVA NEUROTHERAPEUTICS SA: COMPANY OVERVIEW 189
TABLE 188 ALEVA NEUROTHERAPEUTICS SA: PRODUCT APPROVALS 189
10.1.11 THERANICA BIO-ELECTRONICS LTD. 190
TABLE 189 THERANICA BIO-ELECTRONICS LTD.: COMPANY OVERVIEW 190
TABLE 190 THERANICA BIO-ELECTRONICS LTD.: PRODUCT APPROVALS 190
10.1.12 NEURONETICS 191
TABLE 191 NEURONETICS: COMPANY OVERVIEW 191
FIGURE 38 NEURONETICS: COMPANY SNAPSHOT 192
10.1.13 AXONICS 193
TABLE 192 AXONICS: COMPANY OVERVIEW 193
FIGURE 39 AXONICS: COMPANY SNAPSHOT 193
TABLE 193 AXONICS: PRODUCT APPROVALS 194
TABLE 194 AXONICS: DEALS 194
10.1.14 BIOINDUCTION 195
TABLE 195 BIOINDUCTION: COMPANY OVERVIEW 195
10.2 OTHER PLAYERS 196
10.2.1 GIMER MEDICAL 196
10.2.2 NALU MEDICAL INC. 196
10.2.3 HELIUS MEDICAL TECHNOLOGIES 197
10.2.4 MICROTRANSPONDER 197
10.2.5 MAGSTIM 198
10.2.6 ELECTROCORE, INC. 198
10.2.7 RENISHAW PLC 199
10.2.8 TVNS TECHNOLOGIES GMBH 199
10.2.9 BIOWAVEGO USA 200
10.2.10 BIOTRONIK 200
10.2.11 SALUDA MEDICAL PTY LTD. 201
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
 
11 APPENDIX 202
11.1 DISCUSSION GUIDE 202
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 207
11.3 CUSTOMIZATION OPTIONS 209
11.4 RELATED REPORTS 209
11.5 AUTHOR DETAILS 210



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • ニューロモデュレーションのグローバル市場：内部ニューロモデュレーション、脊髄刺激（SCS）、脳深部刺激（DBS）、迷走神経刺激（VNS）、その他
  • 電気刺激装置（ESD）のグローバル市場展望 2023年-2029年：脊髄刺激（SCS）装置、脳深部刺激（DBS）装置、迷走神経刺激（VNS）装置、仙骨神経刺激（SNS）装置、胃電気刺激（GES）装置、経皮電気神経刺激（TENS）装置、神経筋電気刺激（NMES/EMS）装置、その他
  • 低周波正弦波神経刺激治療装置の世界市場2022：脊髄刺激（SCS）、胃電気刺激（GES）、脳深部刺激（DBS）、仙骨神経刺激（SNS）、迷走神経刺激（VNS）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(BT3571-24 )"ニューロモデュレーションのグローバル市場予測（～2028）：内部（脊髄刺激、脳深部刺激）、外部（経頭蓋磁気刺激）" (英文：Neuromodulation Market by Type (Internal (Spinal Cord Stimulation, Deep Brain Stimulation), External (Transcranial Magnetic Stimulation), Application (Tremor, Epilepsy, Parkinson's Disease, Depression, Gastroparesis), and Region - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。